279 related articles for article (PubMed ID: 29472112)
1. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
3. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
4. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
[TBL] [Abstract][Full Text] [Related]
8. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
10. [Effect of immunoglobulin heavy/light chain detection on the minimal residual disease monitoring in IgG multiple myeloma patients].
Zhang H; Zhou L; Li R; He J; Peng Z; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):95-8. PubMed ID: 25778881
[TBL] [Abstract][Full Text] [Related]
11. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
12. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy.
Wolff F; Debaugnies F; Rozen L; Willems D; Brohet F; Brauner J; Stordeur P
Clin Biochem; 2013 Jan; 46(1-2):79-84. PubMed ID: 23041246
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
15. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
16. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
Kraj M
Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
[TBL] [Abstract][Full Text] [Related]
19. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
[TBL] [Abstract][Full Text] [Related]
20. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
